Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Daly

Showing results (411-420 of 511) with videos related to

Pageof 52
Sort By:
Cancer|August 3, 2021
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statementGennady Bratslavsky, Neil Mendhiratta, Michael Daneshvar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Arthritis and Rheumatism|May 14, 2013
Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferationAlexandre Belot, Paul R Kasher, Eleanor W Trotter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
American Journal of Human Genetics|December 1, 2014
Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in TXNL4A causes Burn-McKeown syndromeDagmar Wieczorek, William G Newman, Thomas Wieland, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Cancer Research|May 20, 2016
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and CisplatinYifan Wang, Andrea J Bernhardy, Cristina Cruz, et al.
Pageof 52

Showing results (411-420 of 511) with videos related to

Sort By:
Pageof 52
Cancer|August 3, 2021
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statementGennady Bratslavsky, Neil Mendhiratta, Michael Daneshvar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Arthritis and Rheumatism|May 14, 2013
Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferationAlexandre Belot, Paul R Kasher, Eleanor W Trotter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
American Journal of Human Genetics|December 1, 2014
Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in TXNL4A causes Burn-McKeown syndromeDagmar Wieczorek, William G Newman, Thomas Wieland, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Cancer Research|May 20, 2016
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and CisplatinYifan Wang, Andrea J Bernhardy, Cristina Cruz, et al.
Pageof 52